Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AGBL2 | Q5U5Z8 | 2/20 | 0.40 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25564576 | 0.84 | HCAR2 (0.47) | HCAR2SLC6A3SMN1; SMN2ERCC5ALDH1A1 | |
| SCHEMBL16793195 | 0.82 | SMN1; SMN2 (0.46) | HCAR2SLC6A3SMN1; SMN2ERCC5ALDH1A1 | |
| SCHEMBL11568943 | 0.81 | HCAR2 (0.48) | HCAR2SLC6A3ERCC5ALDH1A1P4HTM | |
| SCHEMBL14347102 | 0.80 | HCAR2 (0.42) | HCAR2SLC6A3SMN1; SMN2ERCC5ALDH1A1 | |
| SCHEMBL25562760 | 0.79 | HCAR2 (0.43) | HCAR2SLC6A3SMN1; SMN2ERCC5ALDH1A1 | |
| SCHEMBL14549193 | 0.79 | SMN1; SMN2 (0.51) | HCAR2SLC6A3SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1706362 | 0.78 | SMN1; SMN2 (0.39) | HCAR2SMN1; SMN2AGBL2ALDH1A1MAPT | |
| SCHEMBL13851672 | 0.78 | HCAR2 (0.46) | HCAR2SLC6A3SMN1; SMN2ERCC5ALDH1A1 | |
| SCHEMBL11566214 | 0.78 | SMN1; SMN2 (0.71) | HCAR2SMN1; SMN2ALDH1A1MAPTGAA | |
| SCHEMBL28861538 | 0.78 | SMN1; SMN2 (0.49) | SLC6A3SMN1; SMN2ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119265552-A | Chemical nickel-plating palladium-gold solution | 生益电子股份有限公司 | 2025-01-07 | — | — | CN | claimed |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4673137-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| EP-4236937-B1 | PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-119265552-A | Chemical nickel-plating palladium-gold solution | 生益电子股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| CN-113330000-B | 3-Carbonylamino-5-cyclopentyl-1 FI-pyrrole compounds having inhibitory activity on CDK2 | 辉瑞公司 | 2024-12-24 | — | — | CN | disclosed |
| WO-2024182736-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | SIONNA THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-11897899-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | SHIONOGI & CO., LTD. (JP) | 2024-02-13 | — | — | US | disclosed |
| US-7691852-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| EP-2041158-A2 | PEPTIDE EPOXYKETONES FOR PROTEASOME INHIBITION | Proteolix, Inc. (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2007149512-A2 | PEPTIDE EPOXYKETONES FOR PR0TEAS0ME INHIBITION | PROTEOLIX, INC. (US) | 2007-12-27 | — | — | WO | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293465-A1 | Compounds for enzyme inhibition | PROTEOLIX, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| US-4053618-A | ANTILIPOLYTIC | ROUSSEL-UCLAF (FR) | 1977-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897899-B2 | Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect | DRD3, DRD4, DRD2 | HCAR2 1109/4885SLC6A3 19/4885SMN1; SMN2 3367/4885 |
| US-20250270172-A1 | Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto | HTR2A, HTR5A, HTR1A | HCAR2 147/4885SLC6A3 42/4885SMN1; SMN2 2147/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | HCAR2 45/4885SLC6A3 3435/4885SMN1; SMN2 4482/4885 |
| US-12559462-B2 | Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | HTR2C, HTR1A, HTR2A | HCAR2 87/4885SLC6A3 59/4885SMN1; SMN2 1918/4885 |
| US-20240294506-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | HCAR2 4411/4885SLC6A3 4594/4885SMN1; SMN2 1988/4885 |
| US-20070293465-A1 | Compounds for enzyme inhibition | PSME1, PSMB1, PSME3 | HCAR2 4446/4885SLC6A3 4832/4885SMN1; SMN2 2198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.